Table 1 Correlations between VEGF-C and MT1-MMP expression and the clinicopathological features of 106 breast cancers
From: MT1-MMP in breast cancer: induction of VEGF-C correlates with metastasis and poor prognosis
| Â | VEGF-C expression | MT1-MMP expression | ||||
|---|---|---|---|---|---|---|
| Â | Positive | Negative | P | Positive | Negative | P |
Tumour | Â | Â | Â | Â | Â | Â |
  T1 | 14 (60.9%) | 9 (39.1%) | 0.023 | 11 (47.8%) | 12 (52.2%) | 0.247 |
  T2 | 30 (51.7%) | 28 (48.3%) |  | 23 (39.7%) | 35 (60.3%) |  |
  T3 | 7 (41.2%) | 10 (58.8%) |  | 5 (29.4%) | 12 (70.6%) |  |
  T4 |  | 8 (100%) |  | 1 (12.5%) | 7 (87.5%) |  |
N | Â | Â | Â | Â | Â | Â |
  N0 | 25 (67.6%) | 12 (32.4%) | 0.002 | 23 (62.2%) | 14 (37.8%) | <0.001 |
  N1 | 21 (45.7%) | 25 (54.3%) |  | 15 (32.6%) | 31 (67.4%) |  |
  N2 | 5 (21.7%) | 18 (78.3%) |  | 2 (8.7%) | 21 (91.3%) |  |
Stage | Â | Â | Â | Â | Â | Â |
  I | 7 (77.8%) | 2 (22.2%) | 0.002 | 6 (66.7%) | 3 (33.3%) | <0.001 |
  II | 39 (54.2%) | 33 (45.8%) |  | 32 (44.4%) | 40 (55.6%) |  |
  III | 5 (20.0%) | 20 (80.0%) |  | 2 (8.0%) | 23 (92.0%) |  |
ER | Â | Â | Â | Â | Â | Â |
  Positive | 21 (35.0%) | 39 (65.0%) | 0.002 | 41 (68.3%) | 19 (31.7%) | 0.1409 |
  Negative | 30 (65.2%) | 16 (34.8%) |  | 25 (54.3%) | 21 (45.7%) |  |
PR | Â | Â | Â | Â | Â | Â |
  Positive | 27 (42.2%) | 37 (57.8%) | 0.132 | 43 (67.2%) | 21 (32.8%) | 0.1967 |
  Negative | 24 (57.1%) | 18 (42.9%) |  | 23 (54.8%) | 19 (45.2%) |  |
Her2 | Â | Â | Â | Â | Â | Â |
  Positive | 24 (42.1%) | 33 (57.9%) | 0.181 | 37 (64.9%) | 20 (35.1%) | 0.5440 |
  Negative | 27 (55.1%) | 22 (57.9%) |  | 29 (59.2%) | 20 (40.8%) |  |